Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, shares in Thousands		3 Months Ended
	Jul. 01, 2015	Mar. 31, 2016 USD ($) segment $ / shares shares	Mar. 31, 2015 USD ($) shares	Dec. 31, 2015 USD ($)
Line of Credit Facility [Line Items]
Common stock conversion ratio	0.125
Anti-dilutive securities excluded from computation of earnings per share amount | shares		144	155
Number of business segments | segment		1
Contract manufacturing revenue		$ 9,206,000	$ 4,181,000
Cost of contract manufacturing		7,804,000	$ 3,923,000
Accounting Standards Update 2015-03 | Prepaid Expenses, Other Assets and Long Term Debt, Current
Line of Credit Facility [Line Items]
Deferred Finance Costs, Net				$ 93,000
Accounting Standards Update 2015-03 | Other Assets and Long Term Debt, Noncurrent
Line of Credit Facility [Line Items]
Deferred Finance Costs, Net				$ 72,000
Continuing Operations
Line of Credit Facility [Line Items]
Contract manufacturing revenue		$ 800,000
Change in Estimate, Effect of Change on Basic and Diluted Earnings Per Share | $ / shares		$ 0.03
Continuing Operations | Excess Capacity and Scrap
Line of Credit Facility [Line Items]
Contract manufacturing revenue		$ 2,900,000
Cost of contract manufacturing		$ 2,800,000
Endo Ventures Supply Agreement | Minimum
Line of Credit Facility [Line Items]
Term of supply agreement		8 years
Zohydro ER and Sumavel DosePro
Line of Credit Facility [Line Items]
Period to accept returned unused product prior to expiration		6 months
Period to accept returned unused product after product expiration		12 months
Short-term investments
Line of Credit Facility [Line Items]
Impairment loss on investments		$ 5,500,000